Key takeaways
Vumerity (diroximel fumarate) and Tysabri (natalizumab) are both used to treat relapsing forms of multiple sclerosis (MS), but they have some key differences. Vumerity is a fumaric acid derivative taken orally twice a day, while Tysabri is a monoclonal antibody given as an IV infusion once a month. Tysabri can also be used to treat Crohn’s disease that hasn’t responded well to other treatments. Both medications are thought to work by reducing inflammation. Tysabri requires enrollment in the TOUCH Prescribing Program due to its risk of serious infections like progressive multifocal leukoencephalopathy (PML). Vumerity can also cause serious side effects like liver damage, infections, and severe allergic reactions. Both medications can be expensive as they are only available as a brand-name forms.
